دورية أكاديمية
Advances in Dietary Phenolic Compounds to Improve Chemosensitivity of Anticancer Drugs.
العنوان: | Advances in Dietary Phenolic Compounds to Improve Chemosensitivity of Anticancer Drugs. |
---|---|
المؤلفون: | Bouyahya A; Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Mohammed V University, Rabat 10106, Morocco., Omari NE; Laboratory of Histology, Embryology, and Cytogenetic, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat 10100, Morocco., Bakrim S; Geo-Bio-Environment Engineering and Innovation Laboratory, Molecular Engineering, Biotechnologies, and Innovation Team, Polydisciplinary Faculty of Taroudant, Ibn Zohr University, Agadir 80000, Morocco., Hachlafi NE; Microbial Biotechnology and Bioactive Molecules Laboratory, Sciences and Technologies Faculty, Sidi Mohmed Ben Abdellah University, Fez 30050, Morocco., Balahbib A; Laboratory of Biodiversity, Ecology, and Genome, Faculty of Sciences, Mohammed V University, Rabat 10056, Morocco., Wilairatana P; Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand., Mubarak MS; Department of Chemistry, The University of Jordan, Amman 11942, Jordan. |
المصدر: | Cancers [Cancers (Basel)] 2022 Sep 21; Vol. 14 (19). Date of Electronic Publication: 2022 Sep 21. |
نوع المنشور: | Journal Article; Review |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
مستخلص: | Despite the significant advances and mechanistic understanding of tumor processes, therapeutic agents against different types of cancer still have a high rate of recurrence associated with the development of resistance by tumor cells. This chemoresistance involves several mechanisms, including the programming of glucose metabolism, mitochondrial damage, and lysosome dysfunction. However, combining several anticancer agents can decrease resistance and increase therapeutic efficacy. Furthermore, this treatment can improve the effectiveness of chemotherapy. This work focuses on the recent advances in using natural bioactive molecules derived from phenolic compounds isolated from medicinal plants to sensitize cancer cells towards chemotherapeutic agents and their application in combination with conventional anticancer drugs. Dietary phenolic compounds such as resveratrol, gallic acid, caffeic acid, rosmarinic acid, sinapic acid, and curcumin exhibit remarkable anticancer activities through sub-cellular, cellular, and molecular mechanisms. These compounds have recently revealed their capacity to increase the sensitivity of different human cancers to the used chemotherapeutic drugs. Moreover, they can increase the effectiveness and improve the therapeutic index of some used chemotherapeutic agents. The involved mechanisms are complex and stochastic, and involve different signaling pathways in cancer checkpoints, including reactive oxygen species signaling pathways in mitochondria, autophagy-related pathways, proteasome oncogene degradation, and epigenetic perturbations. |
References: | Oncol Rep. 2021 Mar;45(3):1133-1141. (PMID: 33650657) Int J Mol Cell Med. 2021 Winter;10(1):11-22. (PMID: 34268250) Environ Sci Pollut Res Int. 2022 May;29(21):31025-31041. (PMID: 35119637) Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Mar;32(6):447-456. (PMID: 29737742) Cancers (Basel). 2021 Apr 22;13(9):. (PMID: 33922395) Oncotarget. 2017 May 30;8(47):82085-82091. (PMID: 29137246) Toxicol Lett. 2014 Jan 3;224(1):157-64. (PMID: 24148603) Cancer Cell Int. 2014 Jul 18;14:71. (PMID: 25788859) Carcinogenesis. 2019 May 14;40(3):412-421. (PMID: 30596962) Int J Clin Exp Pathol. 2014 Jun 15;7(7):3938-47. (PMID: 25120770) J Food Drug Anal. 2019 Oct;27(4):887-896. (PMID: 31590760) Oncol Lett. 2012 Oct;4(4):775-778. (PMID: 23226792) J Cancer. 2016 Jan 10;7(4):353-63. (PMID: 26918049) Carcinogenesis. 2013 Aug;34(8):1806-14. (PMID: 23563091) Phytomedicine. 2018 Apr 1;43:37-45. (PMID: 29747752) Anticancer Drugs. 2019 Mar;30(3):251-259. (PMID: 30489290) Phytother Res. 2021 Nov;35(11):6063-6079. (PMID: 34679214) Climacteric. 2022 Aug;25(4):362-368. (PMID: 35147073) J Med Chem. 2006 Nov 16;49(23):6742-59. (PMID: 17154505) Nutr Cancer. 2022;74(3):761-778. (PMID: 34047218) Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1252-61. (PMID: 16253780) Anticancer Agents Med Chem. 2015;15(9):1185-9. (PMID: 25612678) Onco Targets Ther. 2020 Jan 16;13:513-523. (PMID: 32021294) J Hepatol. 2007 Feb;46(2):222-9. (PMID: 17069924) J Funct Foods. 2018 Jan;40:573-581. (PMID: 29576805) J Nutr Biochem. 2019 Jan;63:62-71. (PMID: 30342318) Int J Nanomedicine. 2017 Oct 10;12:7405-7417. (PMID: 29066891) Sci Rep. 2019 Jan 17;9(1):195. (PMID: 30655588) Oncol Rep. 2015 Oct;34(4):1805-14. (PMID: 26238658) Int J Mol Sci. 2021 Jan 06;22(2):. (PMID: 33419064) Int J Biol Sci. 2021 Aug 19;17(13):3595-3607. (PMID: 34512168) World Neurosurg. 2019 Dec;132:e59-e65. (PMID: 31518741) Cancer Chemother Pharmacol. 2006 Apr;57(4):525-32. (PMID: 16172905) Oncol Lett. 2017 Jun;13(6):4974-4978. (PMID: 28588737) Eur J Pharmacol. 2015 Jan 15;747:36-44. (PMID: 25481858) Ginekol Pol. 2013 Jul;84(7):590-5. (PMID: 24032269) Toxicol Appl Pharmacol. 2017 Feb 1;316:27-35. (PMID: 28025107) BMC Cancer. 2010 Jun 11;10:282. (PMID: 20540768) Korean J Physiol Pharmacol. 2020 Sep 1;24(5):413-422. (PMID: 32830148) Oncol Lett. 2018 Feb;15(2):2252-2258. (PMID: 29434932) Turk Neurosurg. 2020;30(6):813-821. (PMID: 31353436) Evid Based Complement Alternat Med. 2015;2015:186436. (PMID: 26089934) Clin Cancer Res. 2022 Jan 15;28(2):318-326. (PMID: 34667026) Acta Pharmacol Sin. 2014 Jun;35(6):832-8. (PMID: 24902789) Anticancer Res. 2012 Oct;32(10):4413-8. (PMID: 23060566) J Nutr Biochem. 2018 Jun;56:205-214. (PMID: 29597147) Mol Biol Rep. 2021 Dec;48(12):7733-7742. (PMID: 34637097) Chem Biol Interact. 2018 Jan 25;280:45-50. (PMID: 29191453) Plants (Basel). 2022 Jun 12;11(12):. (PMID: 35736706) Clin Exp Pharmacol Physiol. 2015 Feb;42(2):146-53. (PMID: 25363523) Biomed Pharmacother. 2019 Jan;109:2327-2334. (PMID: 30551491) Food Chem Toxicol. 2013 Oct;60:83-91. (PMID: 23871783) Eur J Pharmacol. 2016 Sep 5;786:194-203. (PMID: 27262378) Exp Cell Res. 2015 Mar 15;332(2):236-46. (PMID: 25499970) Clin Lung Cancer. 2015 Nov;16(6):e235-43. (PMID: 26050647) Anticancer Agents Med Chem. 2013 Feb;13(2):352-5. (PMID: 22721393) Int J Mol Sci. 2022 Mar 24;23(7):. (PMID: 35408903) Environ Toxicol. 2022 May;37(5):995-1006. (PMID: 35006630) Oncol Rep. 2019 Nov;42(5):2108-2116. (PMID: 31432178) Cells. 2021 Feb 21;10(2):. (PMID: 33669953) Foods. 2022 Jan 16;11(2):. (PMID: 35053967) |
فهرسة مساهمة: | Keywords: cancer; chemotherapy; combination treatment; dietary phenolic compounds; drugs resistance; drugs sensibilization |
تواريخ الأحداث: | Date Created: 20221014 Latest Revision: 20221017 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC9558505 |
DOI: | 10.3390/cancers14194573 |
PMID: | 36230494 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2072-6694 |
---|---|
DOI: | 10.3390/cancers14194573 |